LONDON, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today announced its financial results for the quarter ended June 30, 2023, and recent business highlights.
“We look forward to additional clinical data in the fourth quarter of this year from our clonal neoantigen-reactive T cell (cNeT) therapy for the treatment of advanced NSCLC (CHIRON) and metastatic malignant melanoma (THETIS) and are encouraged by the improved manufacturing performance of our VELOS™ Process 2,” said Dr Iraj Ali, Chief Executive Officer of Achilles Therapeutics. “We are also very excited about the developments in our AI-driven bioinformatics platform PELEUSTM. PELEUS uses a unique multi-region approach to provide validated and accurate identification of personalized clonal neoantigens. Our newly developed neoRankerTM tool is trained on a proprietary dataset of over 10,000 neoantigens and we calculate that it is potentially twice as good at identifying multiple memory T cell responses than existing deep-learning models. We believe this could be highly differentiated in the design of neoantigen vaccines and further strengthens our leadership position in the field of neoantigen identification.”
Business Highlights
Financial Highlights
2H 2023 Focus and Upcoming Events
Members of the Achilles team will participate in the following upcoming conferences. Additional details will be available in the Events & Presentations section of the Company’s website:
About Achilles Therapeutics
Achilles is a clinical-stage biopharmaceutical company developing AI-Powered precision T cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed on the surface of every cancer cell. The Company has two ongoing Phase I/IIa trials, the CHIRON trial in patients with advanced non-small cell lung cancer (NSCLC) and the THETIS trial in patients with recurrent or metastatic melanoma. Achilles uses DNA sequencing data from each patient, together with its proprietary PELEUS™ bioinformatics platform, to identify clonal neoantigens specific to that patient, and then develop precision T cell-based product candidates specifically targeting those clonal neoantigens.
Forward Looking Statements
This press release contains express or implied forward-looking statements that are based on our management's belief and assumptions and on information currently available to our management. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future operational or financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. The forward-looking statements in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should therefore not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.
For further information, please contact:
Investors:
Meru Advisors
Lee M. Stern
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media:
Consilium Strategic Communications
Mary-Jane Elliott, Sukaina Virji, Melissa Gardiner
+44 (0) 203 709 5000
This email address is being protected from spambots. You need JavaScript enabled to view it.
| ACHILLES THERAPEUTICS PLC | ||||||||
| Condensed Consolidated Balance Sheets (Unaudited) (in thousands, except share and per share amounts) (expressed in U.S. Dollars, unless otherwise stated) | ||||||||
| June 30, | December 31, | |||||||
| 2023 | 2022 | |||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 143,711 | $ | 173,338 | ||||
| Prepaid expenses and other current assets | 31,499 | 23,242 | ||||||
| Total current assets | 175,210 | 196,580 | ||||||
| Non-current assets: | ||||||||
| Property and equipment, net | 10,949 | 12,399 | ||||||
| Operating lease right of use assets | 8,373 | 8,081 | ||||||
| Deferred tax assets | 185 | 251 | ||||||
| Restricted cash | 33 | 33 | ||||||
| Other assets | 3,157 | 3,014 | ||||||
| Total non-current assets | 22,697 | 23,778 | ||||||
| TOTAL ASSETS | $ | 197,907 | $ | 220,358 | ||||
| LIABILITIES AND SHAREHOLDERS’ EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 6,886 | $ | 5,187 | ||||
| Income taxes payable | 7 | 326 | ||||||
| Accrued expenses and other liabilities | 7,569 | 8,292 | ||||||
| Operating lease liabilities-current | 4,656 | 4,188 | ||||||
| Total current liabilities | 19,118 | 17,993 | ||||||
| Non-current liabilities: | ||||||||
| Operating lease liabilities-non-current | 3,972 | 4,388 | ||||||
| Other long-term liability | 974 | 933 | ||||||
| Total non-current liabilities | 4,946 | 5,321 | ||||||
| Total liabilities | 24,064 | 23,314 | ||||||
| Commitments and contingencies (Note 12) | ||||||||
| Shareholders’ equity: | ||||||||
| Ordinary shares, £0.001 par value; 40,946,239 and 40,932,727 shares authorized, issued and outstanding at June 30, 2023 and December 31, 2022, respectively | 54 | 54 | ||||||
| Deferred shares, £92,451.851 par value, one share authorized, issued and outstanding at June 30, 2023 and December 31, 2022 | 128 | 128 | ||||||
| Additional paid in capital | 412,201 | 408,844 | ||||||
| Accumulated other comprehensive loss | (13,901 | ) | (21,695 | ) | ||||
| Accumulated deficit | (224,639 | ) | (190,287 | ) | ||||
| Total shareholders’ equity | 173,843 | 197,044 | ||||||
| TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY | $ | 197,907 | $ | 220,358 | ||||
| ACHILLES THERAPEUTICS PLC | ||||||||||||||||
| Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (in thousands, except share and per share amounts) (expressed in U.S. Dollars, unless otherwise stated) | ||||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||||
| OPERATING EXPENSES: | ||||||||||||||||
| Research and development | $ | 13,774 | $ | 14,776 | $ | 27,642 | $ | 27,790 | ||||||||
| General and administrative | 4,318 | 5,770 | 9,003 | 11,725 | ||||||||||||
| Total operating expenses | 18,092 | 20,546 | 36,645 | 39,515 | ||||||||||||
| Loss from operations | (18,092 | ) | (20,546 | ) | (36,645 | ) | (39,515 | ) | ||||||||
| OTHER INCOME, NET: | ||||||||||||||||
| Other income | 1,212 | 3,271 | 2,303 | 4,900 | ||||||||||||
| Total other income, net | 1,212 | 3,271 | 2,303 | 4,900 | ||||||||||||
| Loss before provision for income taxes | (16,880 | ) | (17,275 | ) | (34,342 | ) | (34,615 | ) | ||||||||
| Benefit (Provision) for income taxes | 34 | (14 | ) | (10 | ) | (29 | ) | |||||||||
| Net loss | (16,846 | ) | (17,289 | ) | (34,352 | ) | (34,644 | ) | ||||||||
| Other comprehensive income: | ||||||||||||||||
| Foreign exchange translation adjustment | 3,817 | (19,302 | ) | 7,794 | (26,979 | ) | ||||||||||
| Comprehensive loss | $ | (13,029 | ) | $ | (36,591 | ) | $ | (26,558 | ) | $ | (61,623 | ) | ||||
| Net loss per share attributable to ordinary shareholders—basic and diluted | $ | (0.42 | ) | $ | (0.44 | ) | $ | (0.86 | ) | $ | (0.89 | ) | ||||
| Weighted average ordinary shares outstanding—basic and diluted | 39,899,944 | 39,104,375 | 39,816,528 | 38,998,686 | ||||||||||||
| Last Trade: | US$1.06 |
| Daily Change: | -0.01 -0.93 |
| Daily Volume: | 533,075 |
| Market Cap: | US$43.560M |
November 14, 2024 August 14, 2024 May 08, 2024 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
